Archives

Sony, Olympus launch medical device joint venture

Tuesday, April 16, 2013 02:49 PM

Sony and Olympus have launched Sony Olympus Medical Solutions, a medical business venture that aims to align Sony's cutting-edge electronics technologies in areas such as digital imaging with Olympus' manufacturing and R&D expertise in the area of medical products including lenses and optical technologies in order to bring high-quality medical care to as many people as possible, and contribute to medical advancement worldwide.

More... »

Merck opens new manufacturing facility in Hangzhou, China

Tuesday, April 16, 2013 02:05 PM

Global healthcare company Merck has opened its new pharmaceutical manufacturing facility in Hangzhou, China. The facility, located in the Hangzhou Economic and Technology Area (HEDA), will package Merck medicines for China and the Asia Pacific region and will become a critical part of Merck's global supply chain. 

More... »

inVentiv Health forms strategic alliance with Bell Medical Solutions

Tuesday, April 16, 2013 11:58 AM

inVentiv Health, a global provider of clinical, commercial and consulting services, has formed a strategic alliance with Bell Medical Solutions, a Japanese CRO with more than 700 clinical research associates serving the growing Japanese market.

More... »

Thermo Fisher Scientific to acquire Life Technologies

Tuesday, April 16, 2013 11:29 AM

Thermo Fisher Scientific, a healthcare equipment company, has signed a definitive agreement to acquire Life Technologies, a global biotechnology tools company, for $76.00 in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of net debt at close ($2.2 billion as of year end 2012).

More... »

Catalent Biologics expands into ADCs through license with Redwood Bioscience

Tuesday, April 16, 2013 10:34 AM

Catalent Pharma Solutions has acquired an exclusive license to market Redwood Bioscience's proprietary SMARTag precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs).

More... »

BMS selects Quintiles as preferred central laboratory provider

Tuesday, April 16, 2013 10:06 AM

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, has been chosen as a preferred provider by Bristol-Myers Squibb to provide global support for BMS's central lab work, biomarker testing and assay development for the next five years.

More... »

Royalty Pharma makes firm offer to acquire Elan

Tuesday, April 16, 2013 09:41 AM

Echo Pharma Acquisition (Royalty Pharma) announced the terms of a firm, all cash offer for the entire issued and to be issued share capital of Elan. 

More... »

Pfizer’s palbociclib gets FDA breakthrough label

Friday, April 12, 2013 02:37 PM

Pfizer’s investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the FDA for the potential treatment of patients with breast cancer.

More... »

Lynn Kramer appointed chief clinical officer of Eisai Product Creation Systems

Friday, April 12, 2013 02:13 PM

Eisai has appointed Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems.

More... »

OncoGenex to initiate phase II trial of OGX-427 in non-squamous NSCLC

Friday, April 12, 2013 12:17 PM

OncoGenex Pharmaceuticals, a biopharmaceutical company, plans to initiate an investigator-sponsored, randomized, double-blind, placebo-controlled phase II study, Spruce, evaluating OGX-427 in patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC). The trial will investigate whether adding OGX-427 to carboplatin and pemetrexed therapy can extend progression-free survival (PFS) outcomes.

More... »